LEO Pharma Reports P-III Trial (DELTA 2) Results of Delgocitinib for Chronic Hand Eczema
Shots:
- The P-III trial (DELTA 2) evaluates delgocitinib (JAK-inhibitor) vs cream vehicle in adult patients with CHE. Delgocitinib's long-term effects are being studied in the (DELTA 3) extension trial, which was made available to patients who completed 16wks. of treatment in (DELTA 1 or 2) trials
- The trial met its 1EPs & 2EPs i.e., the therapy showed improvement in CHE after 16wks. of treatment & was found to be well-tolerated. The results from (DELTA 2) trial will be planned to submit for scientific presentation and publication
- LEO & Japan Tobacco collaborated in 2014 in which LEO gained exclusive rights to develop & commercialize delgocitinib for topical use in dermatological indications globally & JT retains rights in Japan
Ref: LEO Pharma | Image: LEO Pharma
Related News:- LEO Pharma Receives the US FDA's Fast Track Designation for Delgocitinib Cream to Treat Moderate-to-Severe Chronic Hand Eczema
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
